NDASUBCUTANEOUSSUSPENSION, EXTENDED RELEASE
Approved
Apr 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Pharmacologic Class:
Atypical Antipsychotic
Clinical Trials (5)
Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant
Started Apr 2021
Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone
Started Jun 2019
69 enrolled
Schizophrenia
A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities
Started Oct 2018
34 enrolled
Schizophrenia
Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting Injection
Started Jan 2018
328 enrolled
Schizophrenia Spectrum and Other Psychotic Disorders
Comparison of the Effectiveness of Brexpiprazole With That of Risperidone
Started Jun 2016
0Schizophrenia
Loss of Exclusivity
LOE Date
Mar 17, 2042
195 months away
Patent Expiry
Mar 17, 2042
Exclusivity Expiry
Apr 28, 2026
Company
Teva
Israel - Petach Tikva